In contrast to the lack of anti-tumor effect of IL-34 or MCSF-1R inhibitor alone, it seems that each of these compounds may enhance the effect of immunotherapy of chemotherapy (41), thus suggesting a promising opportunity for therapeutic intervention in patients with CRC. The gene discussed is IL34; the disease is neoplasm.